Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001 07 05; 345(1):9-16.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.